首页|不同剂量尿激酶对脑出血脑室铸型溶血效果的对比研究

不同剂量尿激酶对脑出血脑室铸型溶血效果的对比研究

A comparative study on the hemolytic effect of different doses of urokinase on intraventricular casting in patients with cerebral hem-orrhage

扫码查看
目的 观察不同剂量尿激酶用于脑室出血铸型的溶血效果.方法 选择脑室出血患者 200 例,将患者随机分为治疗组 1、治疗组 2、治疗组 3、治疗组 4、治疗组 5.五组均行双侧脑室微创穿刺引流术,治疗组 1 予尿激酶灌注 2 万单位;灌注后夹闭 1h开放引流管,次日复查头颅CT.治疗组 2 予尿激酶灌注 4 万单位;灌注后夹闭 1h开放引流管,次日复查头颅CT.治疗组 3 予尿激酶灌注 6 万单位;灌注后夹闭1h开放引流管,次日复查头颅CT.治疗组 4 予尿激酶灌注 8 万单位;灌注后夹闭 1h开放引流管,次日复查头颅CT.治疗组 5 予尿激酶灌注10万单位;灌注后夹闭1h开放引流管,次日复查头颅CT.观察对比五组患者脑室血肿排出量.结果 治疗组 1 血肿排出量为(8.28±1.06)mL,治疗组 2 血肿排出量为(10.70±2.08)mL,治疗组 3 血肿排出量为(14.28±2.34)mL,治疗组 4 血肿排出量为(15.83±2.78)mL,治疗组 5 血肿排出量为(19.93±2.97)mL;并发症(颅内感染发生率):治疗组 1 为 17.95%,治疗组 2 为 5.00%,治疗组 3 为 2.63%,治疗组 4 为 5.00%,治疗组 5为 2.56%.治疗组 1 颅内感染发生率最高,差异有统计学意义;并发症(再出血发生率):治疗组 1 为 0,治疗组 2 为 0,治疗组 3 为 2.63%,治疗组4 为 10.00%,治疗组 5 为 15.38%.提示随着尿激酶剂量的增大,再出血发生率增高,差异有统计学意义.结论 4~6 万单位剂量尿激酶在脑室出血患者中使用最合适,并发症最少.
Objective To observe the hemolytic effect of different doses of urokinase on ventricular hemorrhage casting.Methods 200 pa-tients with ventricular hemorrhage were selected and randomly divided into treatment group 1,treatment group 2,treatment group 3,treatment group 4,and treatment group 5.All patients were underwent bilateral ventricular minimally invasive puncture and drainage,and perfused with 20000U,40000U,60000U,80000U,100000U urokinase in the treatment group 1,treatment group 2,treatment group 3,treatment group 4,treatment group 5,respectively.After perfusion,the drainage tube was clamped for 1 hour and open it,and cranial CT scan was performed the next day.The output of ventricular hematoma in five groups were observed and compared.Results The hematoma output in treatment group 1 was 8.28±1.06 mL,in treat-ment group 2 was 10.70±2.08 mL,in treatment group 3 was 14.28±2.34 mL,in treatment group 4 was 15.83±2.78 mL,and in treatment group 5 was 19.93±2.97 mL.The incidence of intracranial infection in treatment Group 1 was 17.95%,in treatment Group 2 was 5.00%,in treatment Group 3 was 2.63%,in treatment Group 4 was 5.00%,and in treatment Group 5 was 2.56%.The incidence of intracranial infection was highest in treatment group 1,and the difference was statistically significant.The recurrence rate of treatment group 1 was 0,treatment group 2 was 0,treatment group 3 was 2.63%,treatment group 4 was 10.00%,and treatment group 5 was 15.38%.As the dosage of urokinase increases,the incidence of rebleeding increased,and the difference was statistically significant.Conclusion The use of 40000U to 60000U urokinase is most suitable for patients with ventricular hem-orrhage,with minimal complications,and is suitable for clinical promotion.

Different doses of urokinaseVentricular hemorrhagePuncture and drainage

王黎云、李谷

展开 >

312400 嵊州,浙江省嵊州市人民医院

浙江大学医学院附属第一医院

不同剂量 尿激酶 脑室出血 脑室外引流术

浙江省卫生健康面上项目(2021)

2021KY380

2024

浙江创伤外科
温州医学院

浙江创伤外科

影响因子:0.884
ISSN:1009-7147
年,卷(期):2024.29(6)
  • 10